Conclusions: In this first real-world cohorts of patients with PsA and AS Secukinumab has proven to be effective, regardless of PsA subtype, radiographic progression in AS and previous exposure to biologic therapy. The safety profile was favourable and similar to previous studies.

REFERENCE:

Disclosure of Interest: None declared

Abstract AB0834 – Table 1

Abstract AB0834 – Figure 1. Curve Fitting of Change in ASDAS

Conclusions: Anti-TNF therapy had superior improvement than NSAIDs therapy. Anti-TNF should be used for more than 6 months to achieve better and sustained remission and prevent recurrence.

Disclosure of Interest: None declared

Abstract AB0834 – Table 2. Change in ASDAS per month

Adjusted model: gender, age, disease duration, whether NSAIDs were used

Abstract AB0834 – Table 1. Baseline characteristics

mean(SD)/N(%) Anti-TNF users (n=633) Non-anti-TNF users (n=208) P
Age 31.2 (9.0) 29.7 (8.1) 0.040
Disease duration 8.3 (6.2) 8.4 (5.7) 0.869
ASDAS-CRP 2.1 (1.0) 2.6 (1.1) <0.001
Male 535 (84.5%) 166 (79.8%) 0.114
HLA-B27 positivity 495 (78.3%) 176 (89.3%) 0.451
With NSAIDs 526 (99.1%) 162 (98.2%) 0.356

A. Non-adjusted model

B. Adjusted model: gender, age, disease duration, whether NSAIDs were used